SNDX logo

SNDX
Syndax Pharmaceuticals Inc

3,773
Mkt Cap
$1.77B
Volume
1.15M
52W High
$25.59
52W Low
$8.59
PE Ratio
-7.13
SNDX Fundamentals
Price
$19.94
Prev Close
$19.77
Open
$19.78
50D MA
$22.44
Beta
1.16
Avg. Volume
1.49M
EPS (Annual)
-$3.29
P/B
42.42
Rev/Employee
$578,362.42
$1,771.37
Loading...
Loading...
News
all
press releases
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential
Why Syndax Pharmaceuticals (SNDX) is One of the Best Small Cap Stocks to Buy for 10x Potential...
News Placeholder
More News
News Placeholder
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst Upgrade
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% on Analyst Upgrade...
News Placeholder
HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities researchers at HC Wainwright increased their FY2030 EPS estimates for Syndax Pharmaceuticals in a note issued to investors on Friday, May 1st. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of $3...
News Placeholder
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1% - Time to Sell?
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.1% - Should You Sell...
News Placeholder
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00
Barclays raised their price target on Syndax Pharmaceuticals from $35.00 to $37.00 and gave the stock an "overweight" rating in a research note on Friday...
News Placeholder
Syndax Pharmaceuticals Q1 Earnings Call Highlights
Syndax Pharmaceuticals (NASDAQ:SNDX) reported first-quarter 2026 results highlighting more than $100 million in combined net sales for its two commercial products, Revuforj and Niktimvo, as the...
News Placeholder
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.59) by...
News Placeholder
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +17.95% and -7.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth
Nuvation Bio (NUVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
News Placeholder
Syndax Pharmaceuticals (SNDX) Expected to Announce Earnings on Thursday
Syndax Pharmaceuticals (NASDAQ:SNDX) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-syndax-pharmaceuticals-inc-stock...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available